Recruiting studies: Recurrent Skin Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196 Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
Phase 2 · 2 location(s) · Stanford University · NCT06731933 A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793 Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carci
Phase 3 · 28 location(s) · Centre Leon Berard · NCT06692556 Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carci
Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT06580054 Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune Syst
Phase 2 · 38 location(s) · National Cancer Institute (NCI) · NCT07042295 A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients
Phase 1 · 16 location(s) · OncoNano Medicine, Inc. · NCT06022029 Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresect
NA · 3 location(s) · Alpha Tau Medical LTD. · NCT05047094 Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT07156227 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801 Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spre
Phase 3 · 192 location(s) · National Cancer Institute (NCI) · NCT06589804 A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic So
Phase 2 · 119 location(s) · Daiichi Sankyo · NCT06330064 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086 Thermotherapy in Addition to SOC Palliative Radiotherapy
NA · 2 location(s) · King's College London · NCT06659146 TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous
Phase 1 · 2 location(s) · Emory University · NCT06868433 Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radi
NA · 1 location(s) · Emory University · NCT06662058 Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cuta
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04975152 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024 Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285 Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
Phase 1 · 1 location(s) · Emory University · NCT04428671 A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Phase 1 · 38 location(s) · Eli Lilly and Company · NCT06465069

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.